Beatriz López-Centeno1, Carlos Badenes-Olmedo2, Ángel Mataix-Sanjuan1, Katie McAllister3, José M Bellón4,5, Sara Gibbons3, Pascual Balsalobre4,5, Leire Pérez-Latorre4,5, Juana Benedí6, Catia Marzolini3,7, Ainhoa Aranguren-Oyarzábal1, Saye Khoo3, María J Calvo-Alcántara1, Juan Berenguer4,5. 1. Subdirección General de Farmacia y Productos Sanitarios, Servicio Madrileño de Salud, Madrid, Spain. 2. Ontology Engineering Group, Escuela Técnica Superior de Ingeniería Informática, Universidad Politécnica de Madrid, Madrid, Spain. 3. Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom. 4. Unidad de Enfermedades Infecciosas, Hospital General Universitario Gregorio Marañón (Instituto de Investigación Sanitaria Gregorio Marañón [IiSGM]), Madrid, Spain. 5. IiSGM, Madrid, Spain. 6. Departamento de Farmacología, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain. 7. Division of Infectious Diseases & Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland.
Abstract
BACKGROUND: Drug-drug interactions (DDIs) that involve antiretrovirals (ARVs) tend to cause harm if unrecognized, especially in the context of comorbidity and polypharmacy. METHODS: A linkage was established between the drug dispensing registry of Madrid and the Liverpool human immunodeficiency virus (HIV) DDI database (January 2017-June 2017). Polypharmacy was defined as the use of ≥5 non-HIV medications, and DDIs were classified by a traffic-light ranking for severity. RESULTS: A total of 22 945 people living with HIV (PLWH) and 6 613 506 individuals without HIV had received medications. ARV regimens were predominantly based on integrase inhibitors (51.96%). Polypharmacy was higher in PLWH (32.94%) than individuals without HIV (22.16%; P < .001); this difference was consistently observed across all age strata except for individuals ≥75 years. Polypharmacy was more common in women than men in both PLWH and individuals without HIV. The prevalence of contraindicated combinations involving ARVs was 3.18%. Comedications containing corticosteroids, quetiapine, or antithrombotic agents were associated with the highest risk for red-flag DDI, and the use of raltegravir- or dolutegravir-based antiretroviral therapy was associated with an adjusted odds ratio of 0.72 (95% confidence interval, .60-.88; P = .001) for red-flag DDI. CONCLUSIONS: Polypharmacy was more frequent among PLWH across all age groups except those aged ≥75 years and was more common in women. The detection of contraindicated medications in PLWH suggests a likely disconnect between hospital and community prescriptions. Switching to alternative unboosted integrase regimens should be considered for patients with risk of harm from DDIs.
BACKGROUND: Drug-drug interactions (DDIs) that involve antiretrovirals (ARVs) tend to cause harm if unrecognized, especially in the context of comorbidity and polypharmacy. METHODS: A linkage was established between the drug dispensing registry of Madrid and the Liverpool human immunodeficiency virus (HIV) DDI database (January 2017-June 2017). Polypharmacy was defined as the use of ≥5 non-HIV medications, and DDIs were classified by a traffic-light ranking for severity. RESULTS: A total of 22 945 people living with HIV (PLWH) and 6 613 506 individuals without HIV had received medications. ARV regimens were predominantly based on integrase inhibitors (51.96%). Polypharmacy was higher in PLWH (32.94%) than individuals without HIV (22.16%; P < .001); this difference was consistently observed across all age strata except for individuals ≥75 years. Polypharmacy was more common in women than men in both PLWH and individuals without HIV. The prevalence of contraindicated combinations involving ARVs was 3.18%. Comedications containing corticosteroids, quetiapine, or antithrombotic agents were associated with the highest risk for red-flag DDI, and the use of raltegravir- or dolutegravir-based antiretroviral therapy was associated with an adjusted odds ratio of 0.72 (95% confidence interval, .60-.88; P = .001) for red-flag DDI. CONCLUSIONS: Polypharmacy was more frequent among PLWH across all age groups except those aged ≥75 years and was more common in women. The detection of contraindicated medications in PLWH suggests a likely disconnect between hospital and community prescriptions. Switching to alternative unboosted integrase regimens should be considered for patients with risk of harm from DDIs.
Authors: M Gracia Cantillana-Suárez; Maria de Las Aguas Robustillo-Cortés; Antonio Gutiérrez-Pizarraya; Ramón Morillo-Verdugo Journal: Eur J Hosp Pharm Date: 2021-02-24
Authors: E Contreras-Macías; A Gutiérrez-Pizarraya; M A RobustilloCortés; R Morillo-Verdugo Journal: Rev Esp Quimioter Date: 2021-01-27 Impact factor: 1.553
Authors: Jason J Schafer; Neha S Pandit; Agnes Cha; Emily Huesgen; Melissa Badowski; Elizabeth M Sherman; Jennifer Cocohoba; Ayako Shimada; Scott W Keith Journal: Open Forum Infect Dis Date: 2020-12-18 Impact factor: 3.835
Authors: Franco Maggiolo; Giuliano Rizzardini; Jean-Michel Molina; Federico Pulido; Stephane De Wit; Linos Vandekerckhove; Juan Berenguer; Michelle L D'Antoni; Christiana Blair; Susan K Chuck; David Piontkowsky; Hal Martin; Richard Haubrich; Ian R McNicholl; Joel Gallant Journal: Infect Dis Ther Date: 2021-03-09
Authors: M D Cantudo-Cuenca; Antonio Gutiérrez-Pizarraya; Ana Pinilla-Fernández; Enrique Contreras-Macías; M Fernández-Fuertes; F A Lao-Domínguez; Pilar Rincón; Juan Antonio Pineda; Juan Macías; Ramón Morillo-Verdugo Journal: Sci Rep Date: 2021-06-14 Impact factor: 4.379
Authors: C Okoli; A Schwenk; M Radford; M Myland; S Taylor; A Darley; J Barnes; A Fox; F Grimson; I Reeves; S Munshi; A Croucher; N Boxall; P Benn; A Paice; J van Wyk; S Khoo Journal: HIV Med Date: 2020-07-15 Impact factor: 3.180